Veracyte develops genomic and molecular diagnostic tests that help physicians decide when invasive procedures are truly needed. Its assays analyse tissue or other samples in areas such as thyroid, lung and other cancers, aiming to reduce unnecessary surgeries and improve diagnostic clarity. Pathology labs and oncology-focused clinicians are the primary users of its clinical testing services.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 130.2 | — | -1 | — |
| Q3 2025 | 131.9 | — | 19.1 | — |
| Q4 2025 | 140.6 | — | 41.1 | — |
| Q1 2026 | 139.1 | — | 28.7 | — |
| Q2 2026 | 150.3 | 15.5% | 25.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Atlanta Braves Holdings, Inc. (BATRA), EquipmentShare.com Inc. (EQPT), Exponent, Inc. (EXPO), The Vita Coco Company, Inc. (COCO), AXT, Inc. (AXTI), Magnite, Inc. (MGNI)